Britain's cost-effectiveness watchdog reversed its decision against the Johnson & Johnson prostate cancer pill, thanks to the company's new discount offer.
Here's an interesting number for anyone interested in the risks and rewards of drug development: Two of every three analysts and fund managers recently queried by the ISI Group say they expect that new Alzheimer's drugs in late-stage testing at Eli Lilly and Pfizer/J&J will fail.
After months of restricting Doxil treatment to current patients, Johnson & Johnson has opened up its rationing program to new ones.
Johnson & Johnson ($JNJ) made a big move in China this week with the purchase of its first medical device company in that country. It picked up Guangzhou Bioseal Biotech for an undisclosed sum.
The report says spending on branded drugs in the U.S. increased 2.2% in actual dollars to $258 billion from $252 billion, based on data from IMS Health.
Analysts think St. Jude Medical ($STJ) and Edwards Lifesciences ($EW) could be eyed by Johnson & Johnson ($JNJ) as potential pickups.
Johnson & Johnson's Alex Gorsky hung up his hat in the CEO office today. He'll also have to roll up his sleeves.
Resolving manufacturing problems so Johnson & Johnson can get its once well-regarded consumer brands back in consumers hands is Alex Gorsky's first priority as he officially takes the reins as CEO today.
Expect Johnson & Johnson ($JNJ) to start spending some of its $14 billion in cash on medical device deals to help expand its presence in emerging markets once Alex Gorsky becomes CEO.
In reporting an 8% first-quarter earnings decline to shareholders, Novartis acknowledged the company's inability to meet GMPs at a variety of plants played a big role in that dip.